Will SGK public coverage with Allianz Sigorta, Anadolu Sigorta, and Acibadem Sigorta employer plans cover this?

Each insurer assesses named-patient imports case by case. Some reimburse fully when Abecma is on their formulary even if not currently stocked, some reimburse a percentage subject to copay, and many require pre-authorisation. We supply the documentation set that allows your insurer to assess the case; the claim itself sits with you or your hospital.

Is the FDA-approved indication recognised by TITCK?

The TITCK named-patient pathway exists precisely to permit access when the local registration or stocking lags the FDA label. The application documents the FDA indication, the reference-authority approval, and the local gap; TITCK review focuses on the clinical justification rather than re-litigating the FDA decision.

My physician is licensed in one emirate / state / province and the hospital is in another. Is that fine?

Any Turkish-licensed physician practicing in good standing in the jurisdiction of the dispensing facility has signing authority on the clinical justification letter. The Turkish Medical Association (TTB) and the Ministry of Health licensing directorate verifies the active license; the TITCK application records both the prescribing physician and the dispensing facility.

Can I receive Abecma at home?

The dispensing facility must be Turkish-licensed. The hospital outpatient or specialty pharmacy releases the medicine to you after final verification, and you then administer or self-administer at home where the FDA label permits, after the dispensing pharmacy's training. The cold-chain or controlled-storage handoff ends at the dispensing pharmacy; home storage and any handling protocol are part of your patient onboarding kit.

What about competitors or alternative therapies in the same class?

Choice of therapy depends on the patient's full phenotype, prior therapy, and the prescriber's judgment. Reserve Meds coordinates whichever medicine the physician has prescribed; we do not substitute, advise on substitution, or promote one brand over another.

Indicative drug-only band: USD 419,000 to 465,000 per one-time infusion. Delivered quote within 24h.Get my quote

Abecma access in Turkey: the TITCK named-patient pathway

How patients in the Republic of Turkiye legally obtain Abecma (idecabtagene vicleucel) when the locally registered indication, stocked presentation, or payer coverage does not match what the prescribing physician has written.

Last reviewed 2026-05-12 by Reserve Meds clinical and regulatory team.

Quick orientation

Patients in Turkey access Abecma (idecabtagene vicleucel) for relapsed or refractory multiple myeloma after two or more prior lines of therapy including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody through the TITCK named-patient pathway, a the Turkish Medicines and Medical Devices Agency (Turkiye Ilac ve Tibbi Cihaz Kurumu)-administered mechanism that allows a Turkish-licensed physician at a registered facility to import the FDA-labelled product for a specific named patient. This page details the documentation, approval timeline, and real cost in TRY.

Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.

Reserved for you.

How Abecma reaches patients in Turkey

Abecma (idecabtagene vicleucel, an autologous BCMA-directed CAR T-cell therapy from Bristol Myers Squibb and 2seventy bio, FDA-approved March 2021 for triple-class-exposed relapsed or refractory multiple myeloma after two or more prior lines including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody) is not currently listed on the TITCK registered-product database at titck.gov.tr/dinamikmodul/43 as of 2026-06-01. Access is administered under Additional Article 7 of Law No. 1262 on Pharmaceutical and Medical Preparations through the personal-treatment pathway codified in TITCK's Yurt Disindan Ilac Temini ve Kullanimi Kilavuzu (Guideline on Provision and Use of Medicines from Abroad), Revision 14 dated 29 August 2024, available at portal.aifd.org.tr. The treating haematologist files the epicrisis, scientific justification, and prescription with the TITCK Sahsi Tedavide Kullanilacak Ilaclarin Degerlendirilmesi Komisyonu (Commission for Evaluation of Medicines in Personal Treatment). For Abecma specifically, the file must demonstrate confirmed multiple myeloma with measurable disease, documented exposure and refractoriness to at least one IMiD, one proteasome inhibitor, and one anti-CD38 monoclonal antibody per the FDA KarMMa-3 trial enrolment criteria (NCT03651128), a leukapheresis plan agreed with the receiving BMT centre, and a lymphodepleting chemotherapy schedule (fludarabine plus cyclophosphamide). Because Abecma is an individualised cell-therapy product manufactured from the patient's own T cells, the personal-treatment permit is paired with a leukapheresis appointment at the Turkish CAR-T site and a manufacturing slot at the BMS facility before product return for infusion. On clinical approval the dossier routes to USHAS at ushas.com.tr or to the Turkish Pharmacists Association (TEB) at teb.org.tr as the named-patient import channel. Foreign-sourced product registration on the National Drug Tracking System (Ilac Takip Sistemi, ITS) was made mandatory by Resmi Gazete regulation as reported at aa.com.tr, adding a track-and-trace step at receipt.

Where Abecma is dispensed in Turkey

Abecma is an autologous CAR T-cell product administered once intravenously at a JACIE-accredited or equivalently certified cellular-therapy centre after lymphodepleting fludarabine and cyclophosphamide. Patient-side workflow includes apheresis collection, cryopreservation, US shipment of starting material, manufacturing, return shipment, thaw, and infusion under cytokine-release-syndrome and immune-effector-cell-associated neurotoxicity-syndrome monitoring per the FDA REMS programme. The Turkish institutions with adult haematology, BMT, and cellular-therapy capability appropriate to multiple myeloma CAR-T case load include Hacettepe University Adult Haematology and BMT Unit in Ankara at hastane.hacettepe.edu.tr (ESMO Designated Centre of Integrated Oncology); Ankara University Ibni Sina Hospital and Cebeci Adult Haematology and BMT, the longstanding academic BMT programme of the Ankara University Faculty of Medicine; Istanbul University Cerrahpasa Medical Faculty Hospital adult haematology and BMT in Istanbul; Marmara University Pendik Training and Research Hospital adult haematology and BMT in Istanbul; Acibadem Maslak, Altunizade, and Atakent Hospitals adult haematology and BMT programmes accessible at acibademinternational.com; Anadolu Medical Center (Johns Hopkins Medicine affiliate) BMT and cellular-therapy programme in Kocaeli; and Memorial Sisli and Bahcelievler Hospitals adult haematology and BMT programmes in Istanbul. Hacettepe and Anadolu Medical Center are among the centres most frequently cited in Turkish patient-organisation reporting for academic-led CAR-T workflows.

What Abecma costs in Turkey

The US wholesale acquisition cost for Abecma is approximately USD 419,500 for the one-time infusion at the FDA-labelled dose of 300 to 510 million CAR-positive viable T cells, per Bristol Myers Squibb disclosures and Drugs@FDA at accessdata.fda.gov/scripts/cder/daf. No public Turkish Lira benchmark for Abecma is observed on the TITCK pricing tables or in SGK reimbursement publications as of 2026-06-01; do not estimate. Price snapshot: 2026-06-01. Costs layered above the drug cost include validated cryogenic logistics of apheresed starting material to BMS Summit New Jersey and of finished product back to the Turkish CAR-T site (dry-vapour-shipper cryoshippers with continuous monitoring), the receiving centre's apheresis collection fee, hospital fees for the inpatient infusion admission with cytokine-release monitoring (typically a 7 to 14 day inpatient stay extending up to 28 days for severe CRS or ICANS), and the Reserve Meds concierge fee itemised separately on every firm quote. The Central Bank of Turkey TRY/USD spot rate on the snapshot date should be footnoted by the patient's Turkish financial controller at the time of any TRY quote conversion; TRY has been volatile across 2021-2024 per Central Bank of Turkey rate history at tcmb.gov.tr.

Funding and access barriers for Abecma in Turkey

Turkey's Social Security Institution (Sosyal Guvenlik Kurumu, SGK) is the dominant payer for almost all Turkish residents and reimburses named-patient imports under the Saglik Uygulama Tebligi (SUT) section 4.3 framework documented at sgk.gov.tr. Under named-patient personal-treatment use, SGK reimbursement of foreign-sourced medicines is generally available at prices exempt from international reference pricing and mandatory discounts, a posture documented in the Cambridge International Journal of Technology Assessment in Health Care analysis at cambridge.org. For Abecma, the practical sequence is haematology approval at a designated BMT centre, TITCK personal-treatment permit, SGK referral and reimbursement decision before infusion. Private supplementary insurers active in this profile include Acibadem Sigorta, Anadolu Sigorta, Allianz Sigorta, AXA Sigorta, Mapfre Sigorta, and Generali; these typically cover patient out-of-pocket exposure at private facilities and are coverage-tier dependent for unlicensed-import cell therapies. Bristol Myers Squibb US patient assistance programmes do not extend to Turkish residents. The KarMMa-3 trial restricted enrolment to patients aged 18 and older with adequate organ function; Turkish BMT centres apply equivalent screening for cardiac, pulmonary, renal, hepatic, and CNS suitability before accepting apheresis. SGK reimbursement on cellular therapies is the most consequential funding variable Turkish multiple-myeloma families plan around.

Recent regulatory and access news for Abecma

TITCK issued Revision 14 of the Yurt Disindan Ilac Temini ve Kullanimi Kilavuzu on 29 August 2024, the operative reference for any current Abecma personal-treatment file; consolidated PDF at portal.aifd.org.tr. The Anatolian Agency reported the Resmi Gazete regulation making registration of foreign-sourced medicines on the Ilac Takip Sistemi (ITS) mandatory at aa.com.tr, applicable to oncology cell therapies sourced from US and EU manufacturers. TITCK published a clarification statement on Yurt Disindan Ilac Temini following supply and pricing controversies at aa.com.tr. No drug-specific TITCK or SGK bulletin for Abecma over the last 12 months has been observed as of 2026-06-01.

Where Reserve Meds fits in Abecma cases

Reserve Meds is a US-based concierge coordinator. We do not replace your treating physician, we do not replace TITCK, and we do not replace your dispensing pharmacy. For Abecma specifically, we orchestrate the US-side sourcing through a DSCSA-compliant specialty channel, build the documentation packet your physician submits, coordinate validated logistics (cold-chain with continuous temperature logging where the FDA label requires it) into Turkey, and assign a single named coordinator through the case. Standard named-patient coordination under our specialty playbook applies. Presentation selection, dose-band confirmation, and patient onboarding for self-administration where applicable are the recurring operational fundamentals we expect for this drug.

Operationally, a typical Abecma case runs across four parallel tracks. The clinical track is the physician's: justification letter, dosing plan, monitoring schedule, and the next patient-facing follow-up. The regulatory track is the TITCK application packaged by the importer; we provide the documentation template, the dispensing facility license check, and the chain-of-custody attestation. The logistics track is the US-side sourcing and the validated international shipment with continuous temperature logging and customs broker coordination. The patient-experience track is the named coordinator who keeps everyone aligned on dates, addresses dispensing-pharmacy questions, and confirms the medicine has been received and stored correctly. The four tracks are run in parallel rather than in series; that is the operational difference between a 3-week and a 9-week case.

Turkish specialty care concentrates at the Acibadem, American Hospital, and Memorial chains in Istanbul, with Hacettepe University Hospital in Ankara serving as the principal academic referral centre; the TITCK named-patient supply pathway is routed through the Turkish Pharmacists Association (TEB) foreign medicines channel.

Next step

If your Turkish physician has prescribed Abecma and you are weighing the cross-border route, the next step is a short intake. We confirm eligibility within 24 to 48 hours and send a documentation kit to your physician.

Start your Abecma case Or message us on WhatsApp